Innervace is a regenerative therapy company developing technology that acts as pre-formed, anatomically-inspired, implantable tissue pathways to directly replace lost connections due to brain degeneration or injury. Our lead program mimics the lost nigrostriatal pathway in patients with Parkinson’s disease (PD).
Active Portfolio Company
https://www.innervace.com/
Active Portfolio Company
https://www.innervace.com/
Total raised: $40M
Investors 2
| Date | Name | Website |
| - | IP Group N... | ipgroup-in... |
| - | BioAdvance | bioadvance... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.09.2022 | Series A | $40M | - |
Mentions in press and media 2
| Date | Title | Description |
| 08.09.2022 | Innervace Raises $40M Series A Financing | NEW YORK, NY, Innervace, a regenerative medicine company developing the first implantable biofabricated neural pathway to restore brain circuitry, has raised $40 million in a Series A financing. >> Click here for more funding data ... |
| 08.09.2022 | Innervace Raises Up to $40M in Series A Funding | Innervace, a NYC-based regenerative medicine company developing an implantable biofabricated neural pathway to restore brain circuitry, raised up to $40 million in Series A financing. The new round was led by Deerfield Management with parti... |